Arrhythmogenic right ventricular cardiomyopathy/dysplasia

Hellenic Journal of Cardiology

Volumn 52, Issue 5, 2011, Pages 452-461

  Avramides, Dimitrios ^a   Protonotarios, Nikos ^b   Asimaki, Angeliki ^c   Matsakas, Evangelos ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b Yannis Protonotarios Medical Centre   (Greece)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Arrhythmogenic; Cardiomyopathy; Defibrillator; Endomyocardial biopsy; Immunohistochemical; Plakoglobin

Indexed keywords

AMIODARONE; CARVEDILOL; RAMIPRIL; SOTALOL; WARFARIN;

ADD ON THERAPY; ADULT; ARRHYTHMOGENESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE BIOPSY; HEART RIGHT VENTRICLE DYSPLASIA; HOLTER MONITORING; HUMAN; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; OXYGEN CONSUMPTION; PRECORDIAL PAIN; QRS COMPLEX; T WAVE INVERSION; TISSUE DOPPLER IMAGING;

ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; FEMALE; HUMANS; MIDDLE AGED;

EID: 80053064344     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996; 93: 841-842.
2. Protonotarios N, Tsatsopoulou A, Patsourakos P, et al. Cardiac abnormalities in familial palmoplantar keratosis. Br Heart J. 1986; 56: 321-326.
3. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988; 318: 129-133.
4. Protonotarios N, Tsatsopoulou A. Arrhythmogenic right ventricular cardiomyopathy/dysplasia and Naxos disease. Hellenic J Cardiol. 2004; 45: 370-378.
5. Tsatsopoulou AA, Protonotarios NI, McKenna WJ. Arrhythmogenic right ventricular dysplasia, a cell adhesion cardiomyopathy: insights into disease pathogenesis from preliminary genotype-phenotype assessment. Heart. 2006; 92: 1720-1723.
6. Sen-Chowdhry S, Lowe MD, Sporton SC, McKenna WJ. Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. Am J Med. 2004; 117: 685-695.
7. Calkins H. Arrhythmogenic right-ventricular dysplasia/cardiomyopathy. Curr Opin Cardiol. 2006; 21: 55-63.
8. Corrado D, Fontaine G, Marcus FL, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation. 2000; 101: E101-106.
9. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997; 30: 1512-1520.
10. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J. 1994; 71: 215-218.
11. Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol. 2002; 40: 1445-1450.
12. Marcus F, McKenna W, Duane Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Proposed Modification of the Task Force Criteria. Eur Heart J. 2010; 31: 806-814.
13. Yoerger DM, Marcus F, Sherrill D, et al. Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol. 2005; 45: 860-865.
14. Lindström L, Wilkenshoff UM, Larsson H, Wranne B. Echocardiographic assessment of arrhythmogenic right ventricular cardiomyopathy. Heart. 2001; 86: 31-38.
15. Antoniades L, Tsatsopoulou A, Anastasakis A, et al. Arrhythmogenic right ventricular cardiomyopathy caused by deletions in plakophilin-2 and plakoglobin (Naxos disease) in families from Greece and Cyprus: genotype-phenotype relations, diagnostic features and prognosis. Eur Heart J. 2006; 27: 2208-2216.
16. Bomma C, Rutberg J, Tandri H, et al. Misdiagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2004; 15: 300-306.
17. Sievers B, Addo M, Franken U, Trappe H-J. Right ventricular wall motion abnormalities found in healthy subjects by cardiovascular magnetic resonance imaging and characterized with a new segmental model. J Cardiovasc Magn Reson. 2004; 6: 601-608.
18. Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005; 45: 98-103
19. Basso C, Ronco F, Marcus F, et al. Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria. Eur Heart J. 2008; 29: 2760-2771.
20. Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2009; 360: 1075-1084.
21. Vasaiwala SC, Finn C, Delpriore J, et al. Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2009; 20: 473-476.
22. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005; 112: 3823-3832.
23. Nava A, Bauce B, Basso C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2000; 36: 2226-2233
24. Hulot J-S, Jouven X, Empana J-P, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004; 110: 1879-1884.
25. Lemola K, Brunckhorst C, Helfenstein U, Oechslin E, Jenni R, Duru F. Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long term experience of a tertiary care centre. Heart. 2005; 91: 1167-1172.
26. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter- defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/ dysplasia. Circulation. 2003; 108: 3084-3091.
27. Turrini P, Corrado D, Basso C, Nava A, Bauce B, Thiene G. Dispersion of ventricular depolarization-repolarization: a noninvasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation. 2001; 103: 3075-3080.
28. Protonotarios N, Tsatsopoulou A, Anastasakis A, et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. J Am Coll Cardiol. 2001; 38: 1477-1484.
29. Wichter T, Paul M, Wollmann C, et al. Implantable cardioverter/ defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation. 2004; 109: 1503-1508
30. Roguin A, Bomma CS, Nasir K, et al. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2004; 43: 1843-1852.
31. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary. Eur Heart J. 2006; 27, 2099-2140
32. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992; 86: 29-37.
33. Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. 2009; 54: 609-615.
34. Hodgkinson KA, Parfrey PS, Bassett AS, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol. 2005; 45: 400-408.
35. van Tintelen JP, Entius MM, Bhuiyan ZA, et al. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2006; 113: 1650-1658.
36. Guiraudon GM, Klein GJ, Sharma AD, Yee R, Guiraudon CM. Surgical therapy for arrhythmogenic right ventricular adiposis. Eur Heart J. 1989; 10 Suppl D: 82-83.
37. Damiano RJ, Asano T, Smith PK, Cox JL. Effect of the right ventricular isolation procedure on ventricular vulnerability to fibrillation. J Am Coll Cardiol. 1990; 15: 730-736.
38. Protonotarios NI, Tsatsopoulou AA, Gatzoulis KA. Arrhythmogenic right ventricular cardiomyopathy caused by a deletion in plakoglobin (Naxos disease). Card Electrophysiol Rev. 2002; 6: 72-80.
39. Bauce B, Basso C, Rampazzo A, et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J. 2005; 26: 1666-1675.
40. Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation. 2005; 112: 636-642.
41. Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006; 113: 1171-1179.
42. Basso C, Wichter T, Danieli GA, et al. Arrhythmogenic right ventricular cardiomyopathy: clinical registry and database, evaluation of therapies, pathology registry, DNA banking. Eur Heart J. 2004; 25: 531-534.